Evaluation of safety, tolerability and pharmakokinetics of ascending doses of pegylated Interferon α2a (PEGASYS®) in combination with STI-571 (Glivec®) in patients with chronic myelogenous leukemia (CML) in early chronic phase.
Laufzeit: 01.01.2001 - 31.12.2010